We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of FK463 for the Treatment of Invasive Aspergillosis

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00036166
First Posted: May 9, 2002
Last Update Posted: June 16, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Astellas Pharma Inc
May 8, 2002
May 9, 2002
June 16, 2015
January 1999
December 2002   (Final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00036166 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Study of FK463 for the Treatment of Invasive Aspergillosis
An Open-Label, Non-Comparative Study of FK463 for the Treatment of Invasive Aspergillosis
The purpose of the study is to evaluate the safety and efficacy of FK463 in patients with proven or probable invasive infections due to Aspergillus species.
This will be an open-label, non-comparative study of intravenous FK463. Enrollment will include at least 100 patients evaluable for efficacy.
Interventional
Phase 2
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Aspergillosis
Drug: FK463
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
326
December 2002
December 2002   (Final data collection date for primary outcome measure)

Inclusion Criteria

  • Has proven or probable systemic infection with Aspergillus species

Exclusion Criteria

  • Has abnormal liver test parameters, e.g., AST or ALT > 10 times upper limit of normal
  • Has bronchopulmonary aspergillosis, aspergillomas, sinus aspergillosis or external otitis but does not have histologic evidence of tissue invasion
  • Has life-expectancy judged to be less than 5 days
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Austria,   France,   Germany,   Italy,   Poland,   Spain,   Sweden,   United Kingdom
 
 
NCT00036166
FG463-21-01
98-0-046 ( Other Identifier: Alternate Protocol Number )
Not Provided
Not Provided
Not Provided
Astellas Pharma Inc
Astellas Pharma Inc
Not Provided
Not Provided
Astellas Pharma Inc
June 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP